Hemoflex® is a hemostatic gauze to be used in the first urgent aid for temporary control of external arterial, venous or capillary bleeding. Its main active component is chitosan, a biopolymer with hemostatic properties, antibacterial action, biocompatibility, and biodegradation capability.
Topical hemostatic gauze
Bleeding and blood loss are of the main reasons of people death in man-made and natural disasters, accidents and military conflicts. Therefore, one of the most vital issues of the modern urgent medicine especially when large veins or arteries are injured, as well as reliable hemostasis during transportation of the casualty to a medical care unit1,2.
Local hemostatic agents are used as a first urgent medical aid to control bleeding of various intensity both in Russia and abroad. The most widely used external bleeding temporary control products are those based on N-acetyl-1,4-β-D-glucosamine biopolymer, better known as chitosan3,4.
The hemostatic capabilities of chitosan were first mentioned in 1983 when it was shown that contact of the biopolymer with defibrinated/heparinized blood / red blood cells leads to formation of a gel-like blood clot 5. It encouraged use of this biopolymer for manufacturing of the medical hemostatic products.
In-house researches and developments along with the use of innovative biomedical polymer processing technologies enabled introducing a national highly competitive medical product for temporary control of external bleedings, Hemoflex® Combat Hemostatic Sterile Agent. This took place under the Federal Target Program “Development of the Pharmaceutical and Medical Industry of the Russian Federation to 2020 and Beyond”.
In the production of Inmed LLC, a quality management system has been introduced, is functioning and is constantly being improved in accordance with the requirements of ISO 13485 and ISO 9001 quality standards, which is confirmed by the relevant QMS certificates.
The R&D center and quality control team ensures strict compliance with the requirements for the development, production and quality control of products from the selection of a raw material supplier to the quality control of finished products.
In the process of production of products, the parameters of the technological process, as well as the production environment, are continuously monitored.
Each batch of products goes through several stages of intermediate control. At the final stage of quality control, before being sent to the consumer, acceptance tests are carried out, the results of which are recorded in the quality certificate.
The supply of Hemoflex® is necessarily accompanied by a passport that guarantees the quality and authenticity of the products.
Advantages of Hemoflex®
Fast bleeding control
- Lower blood loss
- Lower risk of rebleeding
- Safe application
- Rapid action
- Easy to use
- No animal proteins or clotting factors
- No tissue inflammatory response
- No heat burns
- No risk of embolism
- Sterile and individual package
- No specific preparation before use
Information about packaging
We inform that since mid 2020, Hemoflex® Combat is produced only in green packaging.
Products made in the old version of pixel packaging with an unexpired shelf life have only the following parties:
- 751600270520 (valid until 06.2025)
- 751600320221 valid until 01.2026
For other parties issued in pixel packaging, the expiration date expired.
Please note that the following marking is applied to the Hemoflex® label: the production date, batch number (LOT), sterilization date, QR code.